Bristol's Sale Of HIV Pipeline To ViiV Signals Tightened Focus

Bristol-Myers Squibb Co. on Dec. 18 took another step in narrowing its therapeutic focus by selling its pipeline of HIV candidates, including novel Phase III and Phase IIb assets, to ViiV Healthcare in a pair of deals bringing $350m in upfront cash and significant earn-out potential back to the US-based pharma.

Bristol-Myers Squibb Co. on Dec. 18 took another step in narrowing its therapeutic focus by selling its pipeline of HIV candidates, including novel Phase III and Phase IIb assets, to ViiV Healthcare in a pair of deals bringing $350m in upfront cash and significant earn-out potential back to the US-based pharma.

BMS has been pivoting away from primary care for several years now, making its biggest splash as one of the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category